Sonoma Pharmaceuticals (SNOA) Gross Margin (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Gross Margin of 39.22% for Q1 2026, down 148.0% year-over-year from 81.71% in Q1 2025, and up 3.37% quarter-over-quarter from 37.94% in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Gross Margin (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Gross Margin history runs 17 years deep, the most recent figure standing at 39.22% for Q1 2026.
- In Q1 2026, Gross Margin fell 148.0% year-over-year to 39.22%; the TTM figure through Mar 2026 stood at 37.97% (down 28.0% YoY), while the FY2026 annual figure was 37.97%, down 28.0% from the prior year.
- Gross Margin for Q1 2026 stood at 39.22%, up from 37.94% in the prior quarter.
- The five-year high for Gross Margin was 46.53% in Q4 2023, with the low at 4.18% in Q1 2022.
- The 5-year median for Gross Margin is 37.83% (2025), against an average of 35.44%.
- The sharpest annual moves came in 2022 and 2023: Gross Margin tumbled 1323 bps in 2022, then jumped 2449 bps in 2023.
- Sonoma Pharmaceuticals' Gross Margin stood at 28.23% in 2022, then surged by 65 bps to 46.53% in 2023, then fell by 23 bps to 35.63% in 2024, then increased by 6 bps to 37.94% in 2025, then gained by 3 bps to 39.22% in 2026.
- Business Quant data shows SNOA's Gross Margin at 39.22% in Q1 2026, 37.94% in Q4 2025, and 37.83% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 40.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.23% |
| Mar 31, 2026 | 39.22% |
| Dec 31, 2025 | 37.94% |
| Sep 30, 2025 | 37.83% |
| Jun 30, 2025 | 36.46% |
| Mar 31, 2025 | 40.70% |
| Dec 31, 2024 | 35.63% |
| Sep 30, 2024 | 38.03% |
| Jun 30, 2024 | 38.51% |
| Mar 31, 2024 | 31.72% |
| Dec 31, 2023 | 46.53% |
| Sep 30, 2023 | 36.25% |
| Jun 30, 2023 | 35.13% |
| Mar 31, 2023 | 28.67% |
| Dec 31, 2022 | 28.23% |
| Sep 30, 2022 | 46.11% |
| Jun 30, 2022 | 41.33% |
| Mar 31, 2022 | 4.18% |
| Dec 31, 2021 | 41.45% |
| Sep 30, 2021 | 33.15% |